泊洛妥珠单抗不良反应的回顾性分析

Retrospective Analysis of Adverse Drug Reactions Induced by Polatuzumab Vedotin

关键词:  泊洛妥珠单抗  不良反应  回顾性分析

Key words:  polatuzumab vedotin  adverse drug reactions(ADR)  retrospective analysis

摘要:

目的 分析泊洛妥珠单抗(联合苯达莫司汀+利妥昔单抗)所致不良反应的发生情况及临床特点，为临床安全合理用药提供参考。方法 检索医院信息系统，收集2021年1月—2022年8月在天津市肿瘤医院空港医院住院并使用泊洛妥珠单抗的所有患者的病历资料，记录患者基本信息、用药情况、不良反应发生情况等，进行回顾性分析。结果 纳入分析的患者共7例，其中男性4例(57.1%)、女性3例(42.8%)，主要不良反应包括中性粒细胞减少和白细胞减少。不良反应主要发生在首次用药后3个月内，经对症治疗或观察等待后均可恢复，未发生因不良反应死亡病例。结论 临床合理使用泊洛妥珠单抗时，应加强临床工作者对不良反应的监测和管理，保障患者用药安全性。

Abstract:

OBJECTIVE To study the general situation and characteristics of the adverse drug reactions(ADRs) associated with polatuzumab vedotin(combined with bendamustine and rituximab), so as to provide reference for clinical rational drug use. METHODS The clinical data of all patients who were hospitalized at Tianjin Cancer Hospital Airport Hospital and treated with polatuzumab vedotin during hospitalization from January 2021 to August 2022 were collected by searching Hospital Information System. The basic patient information, medication status, incidence of adverse reactions, etc, were collected and analyzed. RESULTS A total of 7 patients were enrolled in the analysis, which there were 4 males(57.1%) and 3 females(42.8%). The toxicity profile of polatuzumab vedotin consisted mainly of neutropenia and leukopenia. ADRs mainly occured within 3 months after administration, and it could be recovered after symptomatic treatment or observation, and there was no death due to ADRs. CONCLUSION During the rational use of polatuzumab vedotin in clinical practice, clinicians and pharmacists should reinforce the monitoring on its using to ensure the safe and effective of polatuzumab vedotin clinical application.